Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
about
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy SeriesClinical significance of androgen secretion disorders in men with a malignancy.Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateOptimizing bone health and minimizing skeletal morbidity in men with prostate cancerUtilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal OestradiolItalian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Osteoporosis and cancerComparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses.Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid.RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.Management of cancer treatment-induced bone loss.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Challenges of managing elderly men with prostate cancer.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).Medical management of metastatic prostate cancer
P2860
Q30532494-6D91DC49-9B7D-4D94-8157-31E1B257932CQ33840617-47489CC2-FA2D-4671-A858-6054A4919164Q33900049-F1828882-14AA-4031-BF4B-D624CC17BD8DQ34023510-3399EF73-45E1-41DC-AD98-474ED918E968Q34823216-CEA46823-E8DE-4791-9B8F-499EC253A6D0Q35087364-5F0CE8CA-928A-49AF-8727-1174CC281073Q35829609-41906FB2-0920-4369-A268-7A6729847224Q36763196-78B34013-41C2-4A02-972F-4BA85A82451EQ36861650-A4C0749B-0229-4570-88C1-D021BFC349BBQ37135281-E823BD48-E644-4062-854C-85002F753434Q37198504-9960CE95-00DB-441F-B982-CE85B83823B8Q37208464-9777FE41-4D8B-47F8-B061-F7039F0FDB1EQ37225419-9F6EE3D9-9742-4A8F-9472-51620D9B40E5Q37315868-963E97AB-1D1C-4415-9AD1-0D6EE1B617FBQ38090917-8A295DF7-90B8-4244-ADF1-3B455AEFCFD6Q38207463-7A1F7D25-7775-40DF-A75F-856AA51B8119Q38211358-830701A3-3A1A-40D8-B750-1087AD4209F3Q38261253-669FCF5A-1F69-47B9-8513-DD4EA0DA87D8Q38267215-EA7FA875-FE15-4BF2-8ECF-661FC4B435B7Q38493690-38713B7E-4080-4FB6-B05C-C81E7F17CA0FQ45977053-55E86DDE-C582-4CC6-A6BC-251945A0F0EFQ47138098-DBD4EE91-F45A-442C-8CA1-C5182AAFB04DQ47563547-143CDB9B-8A83-476B-932F-5543291C8E90Q53734447-8DF4FBAF-5CA5-47E4-AE7F-2DF13741EED1Q58588895-1B4C7FDD-2603-404D-B61E-D493F1B0A2A2
P2860
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@en
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@nl
type
label
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@en
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@nl
prefLabel
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@en
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@nl
P2093
P2860
P356
P1476
Bisphosphonate therapy in pati ...... atic review and meta-analysis.
@en
P2093
A C L Pompeo
A D Giglio
F L A Fonseca
M A P Esteves
M L Wroclawski
M Tobias-Machado
R B Dos Reis
P2860
P2888
P356
10.1038/PCAN.2011.4
P577
2011-09-06T00:00:00Z
P6179
1010104141